Is It Time To Reconsider Bayer (XTRA:BAYN) After Recent Share Price Recovery?

• If you are wondering whether Bayer's current share price still offers value after recent moves, this breakdown will help you weigh what the numbers are really saying about the stock.
• Bayer's share price recently closed at €40.12, with returns of 1.1% over 7 days, 0.3% over 30 days, 5.6% year to date and 100.0% over 1 year, set against 3 year and 5 year returns of 31.3% decline and 16.3% decline respectively.
• These swings sit against a backdrop of ongoing headlines around Bayer, including product liability settlements, portfolio adjustments and investor reactions to management decisions. All of these factors feed directly into how the market prices risk. Keeping these developments in mind helps explain why short term performance looks so different from the longer term record.
• On Simply Wall St's framework, Bayer currently has a value score of 5 out of 6. The sections ahead will compare what different valuation methods suggest about the stock and finish with a broader way to think about value beyond any single model.

Bayer delivered 100.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Bayer Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It focuses on cash the business might have available for shareholders rather than accounting earnings.

For Bayer, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about €3.3b. Analyst inputs and extrapolated forecasts suggest free cash flow of €6.4b in 2030, with intermediate years including projected figures such as about €3.4b in 2027 and €5.3b in 2029. Simply Wall St extends analyst estimates beyond their usual horizon to build a ten year path of cash flows in euros.

Discounting these cash flows back to today gives an estimated intrinsic value of €214.79 per share. Compared with the recent share price of €40.12, the model implies the stock is 81.3% undervalued based on these assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bayer is undervalued by 81.3%. Track this in your watchlist or portfolio, or discover 236 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Bayer.

Approach 2: Bayer Price vs Sales

For companies where earnings can be affected by one off items or accounting charges, the P/S ratio is often a useful way to compare what investors are paying for each unit of revenue. It sidesteps short term earnings noise and focuses on how the market values the current revenue base.

What counts as a normal P/S ratio depends on what investors expect for future growth and how risky those cash flows appear. Higher expected growth or lower perceived risk usually line up with higher typical multiples, while lower growth or higher uncertainty often come with lower P/S ratios.

Bayer currently trades on a P/S ratio of 0.86x. This sits below the Pharmaceuticals industry average P/S of 2.58x and the peer average of 2.46x. Simply Wall St also calculates a proprietary Fair Ratio of 2.31x, which reflects factors such as Bayer’s earnings growth profile, profit margins, size and company specific risks. This Fair Ratio can be more informative than a simple comparison to peers or the broad industry because it adjusts for Bayer’s own characteristics rather than assuming all companies deserve the same multiple. Set against this Fair Ratio, the current 0.86x P/S suggests the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies.

Upgrade Your Decision Making: Choose your Bayer Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St's Community page let you attach a clear story about Bayer to the numbers by linking your view of its future revenue, earnings and margins to a financial forecast, then to a fair value that you can compare with today’s share price to judge whether it fits your own buy or sell timing. Because Narratives update automatically when new news or earnings arrive, you can see in real time how a more optimistic Bayer view with a fair value of €60.00 and revenue growing 3.7% a year compares with a more cautious view with a fair value of €23.00 and revenue declining 0.1% a year, then decide which story you believe is closer to how Bayer will actually perform.

For Bayer however we will make it really easy for you with previews of two leading Bayer Narratives:

🐂 Bayer Bull Case

Fair value in this bullish Bayer Narrative is set at €60.00 per share.

At the recent share price of €40.12, this implies the shares trade about 33.1% below that fair value based on the narrative assumptions.

The narrative uses an annual revenue growth rate assumption of 3.68%.

• Analysts in this camp expect Bayer to lift revenue and move from a loss today to earnings of €5.2b by around 2029, with profit margins rising into low double digits.
• The view assumes ongoing demand for key pharma products, faster progress in Crop Science productivity, and earlier benefits from digital and precision agriculture.
• Litigation, regulation and high debt are treated as real headwinds, but ones that can be managed within the outlook that underpins the €60.00 fair value.

🐻 Bayer Bear Case

Fair value in this more cautious Bayer Narrative is set at €34.97 per share.

At the recent share price of €40.12, this implies the shares trade about 14.7% above that fair value based on the narrative assumptions.

The narrative uses an annual revenue growth rate assumption of 1.85%.

• Analysts in this group see Bayer growing, but at a slower pace, with profit margins improving into mid single digits and earnings reaching €3.1b by about 2028.
• The case leans heavily on ongoing pressure from litigation, product regulation, patent expiries and competition, which together keep a lid on earnings quality.
• In this view, the current share price already reflects most of the expected progress, so there is limited room for upside if things only play out in line with these assumptions.

Whichever story feels closer to your own expectations for Bayer, the key is to stress test the revenue, margin and litigation assumptions so the share price you are looking at lines up with a narrative you actually believe.

Do you think there's more to the story for Bayer? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com